Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus GEMOX versus GEMOX in first-line advanced biliary tract adenocarcinoma
2009-017428-17Phase 2Completed
- Sponsor
- Azienda Ospedaliera Ordine Mauriziano
- Start
- Feb 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab, gemcitabine and oxaliplatin in biliary adenocarcinoma, cholangiocarcinoma (CCA) and gallbladder adenocarcinoma (2 arms), sponsored by Azienda Ospedaliera Ordine Mauriziano. Primary endpoint: Progression-free survival. Started Feb 2010; status: completed.
02
Drugs
panitumumabgemcitabineoxaliplatin
03
Conditions
biliary adenocarcinomacholangiocarcinoma (CCA)gallbladder adenocarcinoma
Beyond the preview
Go deeper on 2009-017428-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017428-17.